VitaNova Life Sciences annual total liabilities
2018
2019
2020
2021
2022
2023
2024
2025
2026
VitaNova Life Sciences Total Liabilities Growth & History (VNOV)
VitaNova Life Sciences's total liabilities was $395,781 for fiscal 2026.
View full VitaNova Life Sciences company overviewVitaNova Life Sciences annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | $395,781 | $48,214 | +13.87% |
| 2025 | 2025-04-30 | $347,567 | $210,647 | +153.85% |
| 2024 | 2024-04-30 | $136,920 | $68,977 | +101.52% |
| 2023 | 2023-04-30 | $67,943 | $9,852 | +16.96% |
| 2022 | 2022-04-30 | $58,091 | −$116,579 | −66.74% |
| 2021 | 2021-04-30 | $174,670 | $52,094 | +42.50% |
| 2020 | 2020-04-30 | $122,576 | $72,334 | +143.97% |
| 2019 | 2019-04-30 | $50,242 | $44,642 | +797.18% |
| 2018 | 2018-04-30 | $5,600 | — | — |
VitaNova Life Sciences quarterly total liabilities
Q3.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | $395,781 | $48,214 | +13.87% |
| Q3 2026 | 2026-01-31 | $457,975 | $245,186 | +115.22% |
| Q2 2026 | 2025-10-31 | $438,051 | $214,113 | +95.61% |
| Q1 2026 | 2025-07-31 | $379,975 | $180,601 | +90.58% |
| Q4 2025 | 2025-04-30 | $347,567 | $210,647 | +153.85% |
| Q3 2025 | 2025-01-31 | $212,789 | $119,215 | +127.40% |
| Q2 2025 | 2024-10-31 | $223,938 | $131,721 | +142.84% |
| Q1 2025 | 2024-07-31 | $199,374 | $115,912 | +138.88% |
| Q4 2024 | 2024-04-30 | $136,920 | $68,977 | +101.52% |
| Q3 2024 | 2024-01-31 | $93,574 | $27,731 | +42.12% |
| Q2 2024 | 2023-10-31 | $92,217 | $26,774 | +40.91% |
| Q1 2024 | 2023-07-31 | $83,462 | $20,724 | +33.03% |
| Q4 2023 | 2023-04-30 | $67,943 | $9,852 | +16.96% |
| Q3 2023 | 2023-01-31 | $65,843 | $15,352 | +30.41% |
| Q2 2023 | 2022-10-31 | $65,443 | $16,652 | +34.13% |
| Q1 2023 | 2022-07-31 | $62,738 | $30,631 | +95.40% |
| Q4 2022 | 2022-04-30 | $58,091 | −$116,579 | −66.74% |
| Q3 2022 | 2022-01-31 | $50,491 | −$98,616 | −66.14% |
| Q2 2022 | 2021-10-31 | $48,791 | −$97,417 | −66.63% |
| Q1 2022 | 2021-07-31 | $32,107 | −$101,716 | −76.01% |
| Q4 2021 | 2021-04-30 | $174,670 | $52,094 | +42.50% |
| Q3 2021 | 2021-01-31 | $149,107 | $52,868 | +54.93% |
| Q2 2021 | 2020-10-31 | $146,208 | $56,563 | +63.10% |
| Q1 2021 | 2020-07-31 | $133,823 | $63,697 | +90.83% |
| Q4 2020 | 2020-04-30 | $122,576 | $72,334 | +143.97% |
| Q3 2020 | 2020-01-31 | $96,239 | $59,543 | +162.26% |
| Q2 2020 | 2019-10-31 | $89,645 | $89,595 | +179190.00% |
| Q1 2020 | 2019-07-31 | $70,126 | $31,197 | +80.14% |
| Q4 2019 | 2019-04-30 | $50,242 | $44,642 | +797.18% |
| Q3 2019 | 2019-01-31 | $36,696 | −$15,254 | −29.36% |
| Q2 2019 | 2018-10-31 | $50 | −$64,650 | −99.92% |
| Q1 2019 | 2018-07-31 | $38,929 | — | — |
| Q4 2018 | 2018-04-30 | $5,600 | — | — |
| Q3 2018 · Jan 31 | 2018-01-31 | $51,950 | — | — |
| Q3 2018 · Oct 31 | 2017-10-31 | $64,700 | — | — |
VitaNova Life Sciences total liabilities trends
Over the last five fiscal years, VitaNova Life Sciences's total liabilities increased from $174,670 to $395,781, a change of $221,111. The latest reported quarter, Q4 2026, shows $395,781.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review VitaNova Life Sciences source filings ↗